When are quinolones indicated, what are the recommended dosing regimens, and what contraindications and precautions should be considered?

Quinolones: Indications, Dosing, and Safety Considerations

Quinolones are broad-spectrum antibiotics indicated primarily for complicated urinary tract infections, respiratory infections, gastrointestinal infections, and non-tuberculous mycobacterial disease, but their use should be restricted due to serious safety concerns including tendon rupture, QT prolongation, and CNS toxicity—particularly in elderly patients and athletes. 1, 2

Primary Clinical Indications

Respiratory Infections

• Levofloxacin is the preferred quinolone for community-acquired pneumonia, acute otitis media, and sinusitis caused by Streptococcus pneumoniae, Haemophilus influenzae, and Mycoplasma pneumoniae 1
• Dosing: 16-20 mg/kg/day divided every 12 hours (children 6 months-5 years) or 10 mg/kg once daily (children ≥5 years); maximum 750 mg/dose 1

Urinary Tract Infections

• Ciprofloxacin remains effective for UTIs caused by E. coli, Pseudomonas aeruginosa, Enterobacter, Citrobacter, and Serratia species 1
• Oral dosing: 20-40 mg/kg/day divided every 12 hours (maximum 750 mg/dose) 1
• IV dosing: 20-30 mg/kg/day divided every 8-12 hours (maximum 400 mg/dose) 1
• Critical adjustment required: For creatinine clearance <50 mL/min, reduce dose by 50% or double the dosing interval 3

Gastrointestinal Infections

• Ciprofloxacin is indicated for Salmonella and Shigella species infections 1
• However, quinolones should NOT be used for gonorrhea in men who have sex with men (MSM) or infections acquired in California, Hawaii, or through foreign travel due to quinolone-resistant N. gonorrhoeae (QRNG) prevalence exceeding 20% 1

Non-Tuberculous Mycobacterial Disease

• Moxifloxacin 400 mg once daily (oral or IV) is used as part of combination therapy 1
• Pediatric dosing: 7.5-10 mg/kg once daily 1
• Target therapeutic level: 2.5-4 mg/L (peak at 2 hours post-dose) 1

Dosing in Renal Impairment

Levofloxacin Adjustments

• CrCl 20-49 mL/min: 500 mg loading dose, then 250 mg every 24 hours 4
• CrCl 10-19 mL/min: 500 mg loading dose, then 250 mg every 48 hours 4
• CrCl <30 mL/min or hemodialysis: 750-1000 mg three times weekly (NOT daily), administered after dialysis 4
• Rationale: Increasing the dosing interval is preferred over reducing the dose to maintain peak serum concentrations and treatment efficacy 4

Ciprofloxacin Adjustments

• Stage 5 CKD (CrCl <50 mL/min): Reduce to 250 mg twice daily OR 500 mg once every 24 hours 3
• Common pitfall: Using standard twice-daily dosing without adjustment leads to drug accumulation and toxicity 3

Absolute Contraindications

Cardiovascular

• Do NOT use in patients with congenital or acquired QT prolongation, clinically relevant bradycardia, heart failure with reduced ejection fraction, history of symptomatic arrhythmias, or uncorrected hypokalaemia 1
• Baseline ECG required; repeat at 2 weeks and after adding any QT-prolonging medication 1

Tendon Disorders

• Cease immediately if tendinitis suspected—damage or rupture can occur within 48 hours or several months after treatment 1
• High-risk patients: Age >60 years, history of quinolone-related tendon disorders, concomitant corticosteroid use 1, 2
• Athletes: Avoid all quinolone use unless no alternative exists; if prescribed, reduce high-intensity and ballistic activities throughout treatment course 1

Pregnancy and Pediatrics

• Avoid in pregnancy: Animal studies demonstrate arthropathy in weight-bearing joints 1
• Avoid in breastfeeding: Present in milk in animal studies 1
• Moxifloxacin contraindicated in children/adolescents in the UK; use with caution for tuberculosis only 1

Hepatic Disease

• Moxifloxacin contraindicated in Child-Pugh C cirrhosis or transaminases >5× upper limit of normal 1
• Consider levofloxacin as alternative (no hepatic dose adjustment needed) 4

Critical Drug Interactions

Cation-Containing Products

• Separate dosing by ≥2 hours: Aluminum/magnesium antacids, sucralfate, zinc, iron, calcium supplements significantly reduce quinolone absorption 1, 5

QT-Prolonging Medications

• Use with extreme caution: Class IA/III antiarrhythmics, tricyclic antidepressants, macrolides, antipsychotics, ondansetron 1
• Pentamidine increases risk of ventricular arrhythmias 1

Theophylline

• Quinolones increase theophylline levels and seizure risk; reduce theophylline dose and monitor levels 1, 6

Serious Adverse Effects Requiring Monitoring

Common (>1%)

• QTc prolongation (especially with hypokalaemia, proarrhythmic conditions) 1
• Gastrointestinal: nausea, vomiting, diarrhea 1, 7
• CNS: dizziness, headache, confusion 1, 2, 7

Serious but Rare

• Cardiovascular: Torsades de pointes (rare but potentially fatal) 1
• Dermatological: Stevens-Johnson syndrome, toxic epidermal necrolysis 1
• Hematological: Agranulocytosis, aplastic anemia, hemolytic anemia (especially in G6PD deficiency) 1
• Neurological: Seizures (caution in epilepsy, cerebral arteriosclerosis) 1, 2, 5
• Metabolic: Hypoglycemia in diabetic patients on hypoglycemic drugs 1

Monitoring Requirements

• Baseline: ECG, serum creatinine, electrolytes (especially potassium), FBC, LFTs 1, 3
• During therapy: ECG at 2 weeks, blood glucose in diabetics, routine toxicity monitoring (FBC, U&Es, LFTs) intermittently 1
• Renal impairment: Monitor creatinine clearance and electrolytes periodically 4

Special Population Considerations

Elderly Patients (>60 years)

• Increased risk of tendon rupture, CNS adverse effects (confusion, weakness, tremor, depression often mistakenly attributed to aging) 2
• Renal function declines with age; adjust doses for renally excreted quinolones (levofloxacin, ofloxacin) 2
• Use with caution in patients with CNS disorders predisposing to seizures 2

Athletes

• Avoid unless no alternative available 1
• If prescribed: reduce training volume and high-intensity/ballistic activities throughout treatment 1
• Do NOT administer concomitant oral or injectable corticosteroids 1
• Consider magnesium supplementation if no contraindications 1
• Structural tendon changes persist up to 20 weeks post-exposure in animal studies; symptoms can manifest up to 6 months after treatment 1

Myasthenia Gravis

• Risk of exacerbation; use with extreme caution 1

Topical Quinolone Applications

Bacterial Conjunctivitis

• FDA-approved agents (age >12 months): Levofloxacin, moxifloxacin, gatifloxacin, ciprofloxacin, besifloxacin 1
• Systemic toxicity not a concern with topical therapy 1

Acute Otitis Externa/Tympanostomy Tube Otorrhea

• Ciprofloxacin or ofloxacin (with or without corticosteroid) for Pseudomonas aeruginosa, Staphylococcus aureus, mixed organisms 1
• Consider systemic antibiotics for severe acute otitis externa 1

Resistance Considerations

• Fluoroquinolone resistance is increasing: Some areas report E. coli resistance exceeding 20%, particularly among Enterobacteriaceae 8
• Cross-resistance exists among ciprofloxacin, ofloxacin, and levofloxacin (class effect) 8
• QRNG prevalence: 23.9% in MSM vs. 2.9% in heterosexual men; avoid quinolones for gonorrhea in high-risk populations 1
• Inappropriate use worsens antibiotic resistance; reserve quinolones for appropriate indications 7